Ceftolozane Sulfate
The sulfate salt form of ceftolozane, commercially combined with tazobactam as a fixed-dose intravenous preparation for multidrug-resistant gram-negative infections. It is particularly active against Pseudomonas aeruginosa strains resistant to carbapenems. Therapeutic drug monitoring may be considered in patients with fluctuating renal function.
Masse moléculaire
764,8000 g/mol
TPSA
439,00 Ų
Aires thérapeutiques
Mécanisme d'action
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Structure 2D
Cite this structure
Embed this structure
SMILES
Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC(C)(C)C(=O)[O-])c3nsc(N)n3)[C@H]2SC1.O=S(=O)(O)O
InChI
InChI=1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11-;/t12-,18-;/m1./s1
Molecular Formula
C23H32N12O12S3
HBD / HBA
9 / 20
Liaisons Rotatives
12
Atomes Lourds
50
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
The sulfate salt form of ceftolozane, commercially combined with tazobactam as a fixed-dose intravenous preparation for multidrug-resistant gram-negative infections. It is particularly active against Pseudomonas aeruginosa strains resistant to carbapenems. Therapeutic drug monitoring may be considered in patients with fluctuating renal function.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Ceftolozane Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1213250. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 52918380. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ceftolozane-sulfate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ceftolozane-sulfate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ceftolozane-sulfate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ceftolozane-sulfate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ceftolozane-sulfate"></drugfyi-drug>